Consistent with its role as stress response factor, we recently reported that p53 is stabilized in starved HepG2 cells and in mouse and human primary hepatocytes [28], and that p53 is necessary and sufficient for the therapy-enhancing effect of fasting on sorafenib treatment in hepatocellular carcinoma models [29]. The gene discussed is TP53; the disease is hepatocellular carcinoma.